So the two key features of our health care system were as follows. First was banker-organized rationing known as “managed care.” And the second was the rise of vertically integrated giants across every part of the industry, from drug distribution to insurance to hospitals. It was these features, and not the lack of universality, that distinguished U.S. health care from every other nation. Everywhere else, you could ask for the price of medication or service. In America, that price would be, “it depends if you have market power.” The lack of any consistent pricing is the key feature in U.S. health care, in everything from drug distribution and reimbursement to hospital billing to medical supply procurement.
Despite the bitter fights over health care during the Bill Clinton era, the advent of drug benefits for seniors under Bush and Medicare Advantage, and the ACA during Obama’s Presidency, underpinning our health care system was a consensus that corporate power was good. Both sides adopted the ideological goal of eliminating the power of the clinician and the patient, and to move that power to middlemen, who could often control the situation through various forms of pricing choices, like prior authorization or hidden rebates.
I did a story about what happened when Ohio eliminated CVS Caremark and UnitedHealth, from running its drug benefit system for Medicaid. It turns out, the state saved $140 million over two years, even as dispensing fees to pharmacies increased by 1200% on average, and the program got better, with patients able to access 99% of pharmacies. Corporate waste is the main problem in health care.
Other states have also done something like this, with similar success. Abroad, the Japanese run a high quality cheap system. They do not have Medicare for all, there are lots of health insurers. But their government has a list of all treatments with a price next to each treatment. That’s the price. There’s no billing department to fight with other billing departments, there are no quality surveys to give bonus payments to hospitals, no random arbitration firms over price. The price is the price. It’s not like the U.S., where the same procedure or drug could have thousands of different permutations, depending on the insurer, hospital system, physician, and so forth. We could do what Japan does - Medicare has a price list. Just do Medicare prices for all, as Phil Longman keeps suggesting.
Getting rid of corporate power in medicine works.